The ALPS Medical Breakthroughs ETF (SBIO) rose 8.4% in March, driven by a surge in biotech mergers and acquisitions (M&A). Two key holdings, Day One Biopharmaceuticals and Apellis Pharmaceuticals, became acquisition targets in deals totaling $8.1 billion, with their shares soaring over 90%. March saw 22 biotech deals worth $36 billion, a 32% increase from the previous quarter, highlighting strong industry consolidation. SBIO focuses on companies with drugs in late-stage clinical trials, making its holdings attractive for big pharma looking to expand pipelines, which could sustain future gains for the fund.
Synapticure has introduced a virtual ataxia care program to provide specialized neurological care for adults living with ataxias, a group of disorders causing coordination and motor function loss. Partnering with Biogen for awareness, the program off...
Biogen Inc. announced the appointment of Michael J. Parini as its new Chief Legal Officer, effective August 3, 2026. Parini brings over 20 years of legal and strategic leadership in the biopharmaceutical industry, having held senior roles at Spur The...
The LEADER study found that nearly 83% of early Alzheimer's patients remained stable or improved while on LEQEMBI treatment for an average of 17 months, consistent across demographics and genetic profiles. LEQEMBI targets amyloid beta to slow cogniti...
Biogen announced positive Phase 2 results for diranersen, an antisense therapy targeting tau protein in early Alzheimer's disease. The study showed meaningful clinical benefits, including slowing cognitive decline by up to 50% on some measures, and r...
The FDA has approved LEQEMBI IQLIK, a once-weekly subcutaneous injection for initiating treatment of early Alzheimer's disease, allowing at-home dosing. This new form offers a convenient alternative to intravenous infusions, providing flexibility for...
